Modelling the Tox21 10 K chemical profiles for \textit{in vivo} toxicity prediction and mechanism characterization

Ruili Huang\textsuperscript{1}, Menghang Xia\textsuperscript{1}, Srilatha Sakamuru\textsuperscript{1}, Jinhua Zhao\textsuperscript{1}, Sampada A. Shahane\textsuperscript{1}, Matias Attene-Ramos\textsuperscript{1}, Tongan Zhao\textsuperscript{1}, Christopher P. Austin\textsuperscript{1} & Anton Simeonov\textsuperscript{1}

Target-specific, mechanism-oriented \textit{in vitro} assays post a promising alternative to traditional animal toxicology studies. Here we report the first comprehensive analysis of the Tox21 effort, a large-scale \textit{in vitro} toxicity screening of chemicals. We test \textasciitilde{} 10,000 chemicals in triplicates at 15 concentrations against a panel of nuclear receptor and stress response pathway assays, producing more than 50 million data points. Compound clustering by structure similarity and activity profile similarity across the assays reveals structure-activity relationships that are useful for the generation of mechanistic hypotheses. We apply structural information and activity data to build predictive models for 72 \textit{in vivo} toxicity end points using a cluster-based approach. Models based on \textit{in vitro} assay data perform better in predicting human toxicity end points than animal toxicity, while a combination of structural and activity data results in better models than using structure or activity data alone. Our results suggest that \textit{in vitro} activity profiles can be applied as signatures of compound mechanism of toxicity and used in prioritization for more in-depth toxicological testing.

\textsuperscript{1}Division of Pre-clinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, USA. Correspondence and requests for materials should be addressed to R.H. (email: huangru@mail.nih.gov).
The Tox21 programme1–4, a collaboration between the National Institute of Environmental Health Sciences/National Toxicology Program, the US Environmental Protection Agency/National Center for Computational Toxicology, the National Institutes of Health Chemical Genomics Center (now within the National Center for Advancing Translational Sciences) and the US Food and Drug Administration, aims to identify chemical structure–activity signatures derived through in vitro testing that could act as predictive surrogates for in vivo toxicity. During the production phase of the Tox21 programme, the Tox21 10 K compound library has been screened on 30 cell-based assays, including nuclear receptors5 and stress response pathways6, in a quantitative HTS (qHTS) format in triplicate7–10.

Results

Assay performance and activity distribution summary. Twelve of the thirty assays screened performed well in the qHTS format with performance statistics11 including signal-to-background ratios ≥ 3-fold, coefficient of variances ≤ 10% and Z’ factors ≥ 0.5 (Table 1). The other 18 assays, for example, the AR-bla antagonist mode assay, with poorer performance in one or two metrics, for example, lower signal-to-background ratio (< 3), were compensated by better performance in other metrics, for example, extremely small coefficient of variance (< 5%), such that the overall assay performance still withheld as measured by data reproducibility as described below. The positive control titrations embedded in every plate replicated well across the entire screen (Fig. 1) with variations in AC50S < 3-fold for 89% of the assays and < 4-fold for all assays (Table 1). A more direct measure of assay performance is data reproducibility. Reproducibility9 as represented by active match, inactive match, inconclusive and mismatch rates was calculated for all assays (Table 2) screened against the three copies of the 10 K library with compounds plated in different well locations in each copy. Seventeen of the

Table 1 | Tox21 10 K qHTS assay summary statistics*.

| Assay                  | S/B | Z’ factor | CV   | Positive control | Control AC50 | Control AC50 fold change |
|------------------------|-----|-----------|------|------------------|--------------|--------------------------|
| AHR-luc                | 8.4 | 0.3±0.2   | 16±15| Omeprozole        | 49.5μM       | 3.14                     |
| AR-bla agonist         | 1.9±0.2 | 0.2±0.1   | 5±1  | R1881            | 1.21nM       | 2.36                     |
| AR-bla antagonist      | 2.5±0.3 | 0.7±0.2   | 4±1  | Ciproterone acetate | 4.68μM     | 2.51                     |
| ARE-bla                | 2.1±0.3 | 0.7±0.06  | 5±2  | β-Naphthoflavone | 1.95μM       | 1.29                     |
| AR-MDA-luc agonist     | 6.6±0.6 | 0.6±0.06  | 15±2 | R1881            | 14.3pM       | 1.52                     |
| AR-MDA-luc antagonist  | 17±10 | 0.67±0.07 | 8±2  | Nilutamide       | 15.3μM       | 1.49                     |
| Aromatase              | 6.2±0.8 | 0.80±0.03 | 4.7±0.9 | Letrozole        | 6.70nM      | 1.32                     |
| DT40 Rad54/Ku70        | 40±4 | 0.8±0.2   | 6±2  | Tetra-ocyl ammonium bromide | 416nM     | 1.63                     |
| DT40 WT                | 40±7 | 0.79±0.08 | 7±3  | Tetra-ocyl ammonium bromide | 594nM     | 1.79                     |
| DT40 Rev3              | 40±9 | 0.79±0.09 | 6±2  | Tetra-ocyl ammonium bromide | 440nM     | 1.5                     |
| ATAD5                  | 60±0.9 | 0.73±0.04 | 14±2 | 5-Fluorouridine | 2.12μM       | 2.11                     |
| ER-bla agonist         | 4.7±0.6 | 0.53±0.09 | 4±2  | β-Estradiol      | 332pM        | 1.51                     |
| ER-bla antagonist      | 3.3±0.8 | 0.4±0.1   | 11±3 | 4-Hydroxy tamoxifen | 5.13nM     | 1.58                     |
| ER-BG1-luc agonist     | 2.5±0.3 | 0.5±0.2   | 10±5 | β-Estradiol      | 29.0pM       | 3.75                     |
| ER-BG1-luc antagonist  | 8.0±0.9 | 0.77±0.07 | 6±2  | 4-Hydroxy tamoxifen | 73.2nM     | 1.28                     |
| FXR-bla agonist        | 4.0±0.7 | 0.3±0.2   | 7±1  | Chenodeoxycholic acid | 29.8μM     | 1.29                     |
| FXR-bla antagonist     | 4.4±0.9 | 0.67±0.09 | 3±1  | Guggulsterone    | 36.7μM       | 1.3                     |
| TR-beta-luc agonist    | 9±2  | 0.63±0.07 | 12±3 | T3               | 41.9pM       | 2.14                     |
| TR-beta-luc antagonist | 5.0±0.9 | 0.7±0.1   | 6±3  | NA               | NA          | NA                       |
| GR-bla agonist         | 3.0±0.2 | 0.73±0.05 | 3.3±0.8 | Dexamethasone    | 3.64μM       | 1.36                     |
| GR-bla antagonist      | 1.9±0.1 | 0.5±0.1   | 4.8±0.9 | Mifepristone     | 1.71nM       | 2.16                     |
| HSE                    | 3.9±0.5 | 0.46±0.08 | 4±1  | 17-AAG          | 45.3nM       | 1.7                     |
| Mitochondria toxicity  | 6±3  | 0.6±0.2   | 8±3  | FCCP             | 96.2nM       | 2.79                     |
| P53-bla                | 3.1±0.4 | 0.6±0.2   | 6±2  | Mitomycin C      | 1.53μM       | 1.62                     |
| PPAR-delta-bla agonist | 2.5±0.3 | 0.67±0.06 | 6±1  | L-165,041        | 36.4nM       | 1.8                     |
| PPAR-delta-bla antagonist | 2.2±0.2 | 0.57±0.06 | 4.3±0.6 | MK886           | 38.5μM       | 1.95                    |
| PPAR-gamma-bla agonist | 2.4±0.1 | 0.73±0.04 | 5±2  | Rosiglitazone    | 11.8nM       | 1.85                    |
| PPAR-gamma-bla antagonist | 2.1±0.2 | 0.6±0.3   | 5±2  | GW9662          | 2.47nM       | 3.3                     |
| VDR-bla agonist        | 1.9±0.2 | 0.5±0.1   | 5±1  | 1α, 25-Dihydroxy vitamin D3 | 35.0pM     | 1.97                     |
| VDR-bla antagonist     | 2.7±0.2 | 0.55±0.06 | 7±1  | NA               | NA          | NA                       |

AC50 concentration at 50% activity, AC50 fold change = 10^(log AC50/AC50); CV, coefficient of Variance (derived from the negative control wells); NA, not applicable; qHTS, quantitative high-throughput screening; S/B, signal to background.

*Data are derived from the positive and negative control wells on each plate and presented as mean ± standard deviation (n = 408).
thirty assays scored (score = 2 × %active match + %inactive match – %inconclusive – 2 × %mismatch) > 90 (grade A) in terms of reproducibility with <0.5% mismatches in activity (Table 2). Eleven assays had reproducibility scores between 80 and 90 (grade B) with mismatch rates <1%. Only two assays, the wild-type DT40 and the GR-bla antagonist mode assay, scored below 80, but still above 75, with 1–2% mismatch rates. For the same sample, the average AC_{50} differences between the three runs were <2-fold for all the assays (Table 2).

The 30 assays screened against the Tox21 10K collection showed a wide spectrum of activities (Fig. 2) with active rates ranging from 0.43% (VDR-bla agonist mode assay) to 27.4% (DT40 Rad54/Ku70 mutant assay; Fig. 2a) and potencies ranging from subnanomolar to tens of micromolar (Fig. 2b). The average active rate of the 30 assays was 6.5%. The AR-MDA-luc agonist mode assay had the largest fraction of potent compounds (33.3% of actives had AC_{50} < 1 μM), whereas the FXR-bla agonist mode assay had no active compound with AC_{50} < 1 μM.

Clustering compounds by activity profile. The 10 K compounds were grouped into 610 clusters by their activity profile similarity and each cluster was examined for enriched Medical Subject Headings (MeSH; http://www.ncbi.nlm.nih.gov/mesh) pharmacological action (PA) terms (see Online Methods for details). Figure 3 shows the clustered activity profiles and the most significantly enriched MeSH PA term in each cluster (Supplementary Data 1). Of the 553 clusters that contain at least one compound with known MeSH PA (Supplementary Data 1), 544 clusters have significantly enriched terms with P < 0.05 (Fisher’s exact test), 362 clusters with P < 0.01 (Fisher’s exact test) and 89 clusters with P < 0.001 (Fisher’s exact test). This result indicates that compounds with similar activity profiles as determined in the Tox21 screens tend to share similar annotated modes of action (MOAs). For example, all compounds in cluster k36.15 are annotated as cardiotonic agents, including deslanoside, digitoxin, digoxin, ouabain and proscillaridin, which are cardiac glycosides that act by inhibiting Na/K channels. Cluster k30.9 are antineoplastic antimetabolites, with the only exception of N-butyl-N-nitro-N-nitrosoguanidine, which does not have a MeSH PA annotation but is a known DNA alkylating agent.

Figure 1 | Concentration response data of the positive control compounds for the 30 Tox21 phase II assays. (a) Agonist mode assays; (b) antagonist mode assays. The positive control compound is plated as 16-pt. titrations in duplicate in the control columns of every assay plate. In the figure, each concentration response curve is from one plate with a total of 408 plates per assay. The consistency of the control response curves is an indicator of good assay performance.
Another example is cluster k41.4, which is enriched with oestrogenic compounds, such as 17alpha-ethinylestradiol and non-steroidal oestrogens such as diethylstilbestrol and zearalenone (Fig. 3b). A neighbouring cluster, k41.3, contains bisphenol type compounds such as bisphenols A, B, Z and AF. Even though most of the bisphenols do not have a MeSH PA assigned, they are known oestrogenic compounds, as well15. These compounds are not only structurally similar but also share similar activity profiles (Fig. 3b).

Moreover, 537 clusters contain both compounds with known MeSH PA and compounds with no MeSH PA annotation available. If most compounds in the same cluster share similar annotated MOA, then we can use this information to hypothesize on the MOA of the unknown compounds. For example, the pesticide fludioxonil does not have a MeSH PA assigned but co-clustered with the oestrogenic compounds in k41.4, consistent with recent reports on its endocrine disrupting activity16. Similarly, the MeSH term ‘anti-inflammatory agents’ is significantly enriched in cluster k22.1 (Fisher’s exact test: \( P = 4.90 \times 10^{-12} \)). Most of the compounds in this cluster are glucocorticoids with similar steroid type structure. Six out of the sixteen compounds in this cluster do not have MeSH PA annotations, including metformin, a diabetes drug with a distinct structure. Metformin decreases hyperglycemia primarily by suppressing glucose production in the liver (hepatic gluconeogenesis)17; however, the molecular target of metformin is not clearly understood. The present co-clustering of metformin with the anti-inflammatory glucocorticoids indicates that it may act in a manner similar to that of the glucocorticoids. Metformin was identified as an active agonist in both the glucocorticoid receptor (GR) and androgen receptor (AR) assays. Ampiroxicam is another non-steroidal drug found in k22.1 without a MeSH PA annotation. A literature search on ampiroxicam revealed that it is also an anti-inflammatory drug18 supporting the utility of clustering by activity profile as an indicator for compound MOA.

### Table 2 | Assay performances measured by reproducibility of the Tox21 10 K triplicate runs*.

| Assay                     | Active match (%) | Inactive match (%) | Inconclusive (%) | Mismatch (%) | AC50 fold change | Score† |
|---------------------------|------------------|--------------------|------------------|-------------|------------------|--------|
| ATAD5                     | 5.34             | 91.78              | 2.84             | 0.05        | 1.30             | 99.51  |
| DT40 Rad54/Ku70           | 23.92            | 59.47              | 16.50            | 0.10        | 1.32             | 90.61  |
| DT40 Rev3                 | 22.38            | 58.07              | 19.29            | 0.26        | 1.40             | 83.02  |
| DT40 WT                   | 21.07            | 58.89              | 18.65            | 0.39        | 1.76             | 79.58  |
| P53-bla                   | 11.10            | 84.86              | 4.04             | 0.00        | 1.29             | 103.02 |
| ARE-bla                   | 15.29            | 68.34              | 15.65            | 0.70        | 1.76             | 81.85  |
| HSE-bla                   | 7.57             | 86.38              | 6.05             | 0.00        | 1.16             | 94.56  |
| Aromatase                 | 15.94            | 73.08              | 10.66            | 0.30        | 1.16             | 93.66  |
| Mitochondria toxicity     | 17.57            | 67.52              | 14.33            | 0.55        | 1.53             | 87.20  |
| AhR-luc                   | 8.86             | 78.78              | 12.24            | 0.10        | 1.82             | 84.05  |
| AR-bla agonist            | 5.36             | 86.88              | 7.44             | 0.30        | 1.77             | 89.55  |
| AR-bla antagonist         | 15.46            | 75.07              | 9.38             | 0.09        | 1.35             | 96.44  |
| AR-MDA-luc agonist        | 4.14             | 93.65              | 2.20             | 0.00        | 1.36             | 99.74  |
| AR-MDA-luc antagonist     | 13.22            | 76.44              | 10.07            | 0.27        | 1.48             | 92.28  |
| ER-BG1-luc agonist        | 16.43            | 72.47              | 12.05            | 0.28        | 1.52             | 91.46  |
| ER-BG1-luc antagonist     | 12.03            | 79.72              | 7.96             | 0.29        | 1.48             | 95.25  |
| ER-bla agonist            | 7.01             | 87.11              | 5.87             | 0.01        | 1.36             | 95.25  |
| ER-bla antagonist         | 9.84             | 77.86              | 11.95            | 0.34        | 1.49             | 84.90  |
| FXR-bla agonist           | 2.46             | 93.87              | 3.65             | 0.02        | 1.53             | 95.09  |
| FXR-bla antagonist        | 7.50             | 83.04              | 9.35             | 0.11        | 1.73             | 88.48  |
| GR-bla agonist            | 6.67             | 87.49              | 5.75             | 0.10        | 1.37             | 94.89  |
| GR-bla antagonist         | 9.73             | 75.11              | 13.13            | 2.01        | 1.81             | 77.40  |
| PPAR-delta-bla agonist    | 3.46             | 90.79              | 5.71             | 0.04        | 1.71             | 91.91  |
| PPAR-delta-bla antagonist | 5.67             | 86.73              | 7.49             | 0.10        | 1.73             | 90.37  |
| PPAR-gamma-bla agonist    | 8.79             | 83.87              | 7.02             | 0.31        | 1.61             | 93.81  |
| PPAR-gamma-bla antagonist | 8.61             | 79.88              | 11.05            | 0.44        | 1.90             | 85.15  |
| TR-beta-luc agonist       | 2.13             | 90.72              | 7.15             | 0.00        | 1.38             | 87.84  |
| TR-beta-luc antagonist    | 17.15            | 68.35              | 14.18            | 0.32        | 1.39             | 87.82  |
| VDR-bla agonist           | 2.25             | 92.53              | 5.19             | 0.03        | 1.62             | 91.79  |
| VDR-bla antagonist        | 5.41             | 86.41              | 8.11             | 0.08        | 1.53             | 88.97  |

*Active match is the percentage of compounds that were reproducibly active, inactive match is the percentage of compounds that were reproducibly inactive, and mismatch is the percentage of compounds that showed conflicting activities in the triplicate runs. A compound is assigned inconclusive if its activity in the triplicate runs was not clearly active or inactive to make a conclusive reproducibility call. Detailed definitions of the reproducibility calls can be found in our previous report19. AC50 fold change is the average AC50 differences in fold of the active compounds in the triplicate runs.

†Score = 2 × active match + inactive match - inconclusive - 2 × mismatch.

Modelling in vivo toxicity with in vitro and structural data. For benchmarking our models against available in vivo data, we used 72 end points derived from the Registry of Toxic Effects of Chemical Substances database as described in the Methods section. These models are based on compound assay activity profiles clusters (activity-based models) or structure clusters (structure-based models) or both (combined models). The detailed model construction process is described in the Online Methods. The premise for these models is that compounds that share similar in vitro signatures and/or structure features are likely to show similar in vivo effects. We first attempted to build models for each of the 72 end points using the Tox21 phase II assay activity profiles. The average area under the receiver operating characteristic (ROC) curve (AUC-ROC) values from the 100 randomizations of each model are shown in Fig. 4 and listed in Supplementary Table 1. The AUC-ROC values for the 72 toxicity end points ranged from 0.50 (rat multiple dose inhalation) to 0.90 (rat multiple dose intramuscular injection) with an average of 0.64. In all, 7 of the 72 end points had good predictive models with average AUC-ROC values >0.75. There are five human toxicity end points, including standard Draize test
for human skin irritation, multiple dose toxicity data (TDLo) through oral exposure from human females, human males and humans (gender not specified), and reproductive toxicity data (TDLo) through oral exposure from human females. The models built for these end points performed significantly better than the models of the 42 mouse/rat toxicity end points and the 7 rabbit toxicity end points comparing the AUC-ROC values (t-test: \( P < 0.05 \)). The average AUC-ROC values were 0.75 for the human toxicity models, 0.65 for the mouse/rat models and 0.59 for the rabbit toxicity models.

The compound structure-based models showed overall better performance than the activity-based models, underlying the ongoing need to further expand the battery of in vitro assays. The AUC-ROC values for the 72 toxicity end points ranged from 0.59 (rat multiple dose inhalation) to 0.93 (acute toxicity in dog) with an average of 0.78 and 45 of the 72 end points had good predictive models with average AUC-ROC values \( \geq 0.75 \) (Fig. 4 and Supplementary Table 1). However, the models built for toxicity end points from different species did not show any significant difference in their predictive performance. Compared with the activity-based models, the performance improved significantly for the mouse/rat and rabbit toxicity models with average AUC-ROC values increased to 0.77 and 0.76, respectively, but not as significantly for the human toxicity models (average AUC-ROC = 0.81).

We then attempted to combine the compound structure and assay data in an effort to further improve the models. Models were built for only 67 of the 72 toxicity end points because the more stringent criteria (requiring compounds to co-cluster by both structure and activity) used to form the consensus clusters, which were the basis for the combined models, resulted in smaller clusters such that the compounds with data on the remaining 5 end points all became singletons when split into training and test sets. Nevertheless, the combined models built for the 67 end points showed significantly better performance than the structure-based models with an average AUC-ROC of 0.84.
Figure 3 | Clustered activity profiles of the Tox21 10K library. In the heat map, each row is a compound and each column is an assay readout. The heat map is coloured by the compound activity outcome, such that darker red or blue colours indicate more confident activators (red) or inhibitors (blue). Compounds are grouped into clusters of similar activity profiles. Each cluster of compounds is labelled by the most significantly enriched MeSH PA term that cluster measured by a Fisher’s exact test. (a) All 10K compounds; (b) example clusters of oestrogenic compounds.
Activity and structure

Structure

mouse/rat models increased from 0.77 to 0.84 (compared to the average AUC-ROC of 0.78 for the structure-based models; t-test: $P = 1.7 \times 10^{-7}$), and 55 out of the 67 end points achieved AUC-ROC values $>0.75$ (Fig. 4 and Supplementary Table 1). Similar to the structure-based models, the species difference between the model performances disappeared. The animal toxicity models showed a larger improvement in model performance than the human toxicity models, for example, the average AUC-ROC values for the mouse/rat models increased from 0.77 to 0.84 ($P = 3.7 \times 10^{-6}$), whereas the average performance of the human models increased from 0.81 to 0.86 ($P > 0.05$).

Discussion

The Tox21 10 K collection has been screened against 30 assays, yielding high-quality data sets with reproducibility scores $>85$. In this study, we summarized the activities observed from these assays. Further analyses of the data are currently underway to assess the biological relevance of the assay results, that is, whether the actives identified by an assay are truly perturbing the pathway that is purportedly being measured by the assay and not being results of assay artefacts$^{19}$. For this purpose, sets of reference or tool compounds with known activity in these pathways need to be collected to obtain an estimate of the false positive/negative rates of each assay$^{8-10}$. With our current active identification methods$^{9}$, we found that the compound activity profiles or signatures generated across the 30 assays are useful for MOA hypotheses generation and chemical prioritization$^{20}$. Compounds with unknown MOA that share similar profiles with compounds with known MOA could be prioritized and tested for that hypothesized MOA.

We tested the applicability of the assay data to building predictive models for in vivo toxicity end points in comparison with chemical structure data. The predictive performances of most of these models are reasonable but not ideal, and are end point dependent. Our results show that with the current set of assay data chemical structures appear to be more predictive than assay activity profiles for most in vivo toxicity end points. One reason for this could be that the assays we have screened so far only focused on two major areas: nuclear receptor signalling and stress response pathways. Although these pathways are important for toxicity, they are far from encompassing all aspects of biology involved in toxic response. In the continuation of the Tox21 programme, more assays will be included to cover additional pathways and targets that could be relevant for toxicity. Moreover, we have observed that not all assays contribute equally to the predictive power of the models, suggesting that it is important to select the relevant assays and to ensure comprehensive coverage. We checked the predictive capacity of each assay of each in vivo toxicity end point, and for each end point only a few assays were predictive with AUC-ROC $>0.7$ (Supplementary Table 1). Assays that measure cell viability took up over half of the most predictive assays.

Species difference is another important contributing factor to the less-than-ideal performance of the models based on assay data. All of the screening data we used in this analysis are derived from cell-based assays using human cells or cell lines, whereas most of the in vivo data we are trying to model are collected from animals. According to a 2004 Food and Drug Administration report, 92% of new drugs that passed animal testing failed in human clinical trials because of lack of effect or unexpected toxicity$^{21}$. More recent studies show that animal data predicted
human outcomes only around half of the time\textsuperscript{22}. It is thus not surprising that human in vitro cell line data did not show high-predictive power when applied to predict animal toxicity data. To better assess the predictive value of the human in vitro assay data, in vivo human toxicity data, that is, clinical toxicity data presently not readily available to the public, are required.

Comparison of the models for the few human toxicity end points with the models for animal toxicity showed that the assay data-based models performed markedly better in predicting human toxicity than animal toxicity; in contrast, the structure-based models did not show this species selectivity. Consistent with our findings, a previous small-scale study testing 50 compounds reported similar observations that acute human systemic toxicity was predicted better by human cell lines than animal cell lines\textsuperscript{23}. Furthermore, differences in experimental conditions between in vitro and in vivo studies, such as dosage, timing and metabolic capacity differences, could affect the extrapolation from in vitro to in vivo results. Under qHTS conditions, most compounds are tested in a fixed concentration range up to 100 \(\mu\)M, and all of the assays used are short-term assays with compound exposure time ranging from a few hours to a day, whereas for in vivo studies compounds are tested at much wider dose ranges and time spans up to months and years\textsuperscript{24}.

Encouragingly, combining structure and activity information significantly improved the model performance for most of the in vivo end points. This phenomenon has been observed previously and reviewed recently\textsuperscript{25}. Our results further corroborate the value of the in vitro assay data when applied to in vivo toxicity prediction. However, the applicability domain of the combined models is limited by the availability of in vivo data for a number of toxicity end points. This again highlights the importance of having easy access to more high-quality in vivo data.

Data quality is another important factor affecting model performance—a prediction could only be as good as the data it is based on. All measurements have errors or variations associated. In this study, we evaluated the quality of the in vitro qHTS data in terms of reproducibility (Table 2). We also checked the reproducibility of the in vivo data for which we tried to model following a similar approach using compounds with replicate measurements in each in vivo toxicity end point. We found that for those end points with at least 20 compounds that had replicates, there was a significant correlation (Pearson correlation: \(\rho = 0.61, P = 1.51 \times 10^{-5}\)) between the reproducibility of the replicates and the performance (AUC-ROC) of the model built for that end point, such that models built for more reproducible data showed better predictive power (Fig. 5). This observation suggests that improving data quality would help further improve the performance of in vivo toxicity prediction models. The high-quality winning models resulting from the recent Tox21 Data Challenge (https://tripod.nih.gov/tox21/challenge), a crowdsourcing effort that asked participants to build predictive models for the in vitro assay data based on chemical structure, provide additional evidence for the importance of data quality.

In summary, the Tox21 10 K chemical library has been screened against a panel of nuclear receptor and stress response pathway assays, producing the largest set of high-quality in vitro toxicity data known to date. Although data analysis and interpretation are still underway, the compound activity profiles generated from this study have been shown useful for MOA hypotheses generation and chemical prioritization. Here, we built and assessed predictive models for various in vivo toxicity end points using in vitro qHTS data and compound structure data. The in vitro assay data-based models were distinctly better at predicting human toxicity end points than animal toxicity. More human toxicity data and high-quality in vivo data are critical in assessing the true predictive power of in vitro data-based models of in vivo toxicity. Combining structure and activity data resulted in better models than those built with structure or activity data alone reinforcing the value of in vitro assay data in toxicity prediction. The scale and high-resolution nature of the data provided within this screening offer the opportunity for researchers worldwide to derive new insights from this valuable resource in a manner akin to previous crowdsourcing efforts (https://tripod.nih.gov/tox21/challenge)\textsuperscript{26,27}. We have made publicly available all the HTS results (http://www.ncbi.nlm.nih.gov/pcassay?term=tox21) as well as the clustering results used for modelling and the Tox21 compound library information online (http://tripod.nih.gov/tox/filedownload/).

**Methods**

**Tox21 chemical library.** The Tox21 10 K library consists of compounds mostly procured from commercial sources by the Environmental Protection Agency (http://www.epa.gov/nct/dstox/sdf/tox21s.html), National Toxicology Program and National Institutes of Health Chemical Genomics Center\textsuperscript{28}, for a total of greater than 10,000 plated compound solutions consisting of 8,599 unique chemical structures and annotations of the Tox21 10 K library have been deposited into PubChem (http://www.ncbi.nlm.nih.gov/pcsubstance?term=tox21).

**Assays and qHTS data analysis.** Two areas were the initial focus in the Tox21 phase II screening including nine nuclear receptor targets and seven stress response pathways, selected based on their biological and toxicological relevance, public interest and adaptability to miniaturization and automated screening. The assays were run in different modes (agonist versus antagonist) and/or formats (full length versus partial receptor) as detailed below, totaling 30 assays. Two reporter gene systems, \(\beta\)-lactamase (bla) and luciferase (luc), were used in this study\textsuperscript{5}. All cell-based assays were multiplexed with a cell viability assay in the same assay well. Although bla-based assays were multiplexed with a luminescence-based cell viability assay (CellTiter-Glo viability assay, Promega), luc-based assays were multiplexed with a fluorescence-based cell viability assay (Cell Titer-Fluor viability assay, Promega). The nuclear receptor assays, including oestrogen receptor alpha, ligand-binding domain (ER-bla), oestrogen receptor alpha, full length (ER-BCI-luc), androgen receptor, ligand-binding domain (AR-bla), androgen receptor, full length (AR-MDA-luc), glucocorticoid receptor (GR-bla), farnesoid X receptor...
(FXR-bla), peroxisome proliferator-activated receptor delta (PPAR-delta-bla), peroxisome proliferator-activated receptor gamma (PPAR-gamma-bla), thyroid hormone receptor (TR-luc), vitamin D receptor (VDR-bla) and aryl hydrocarbon receptor (AHR-luc) assays, were screened in both agonist and antagonist modes. Aromatase[^20,30] mitochondria[^31] and DNA repair deficient isogenic chicken DT40 cell viability (DT40) assays[^32] were screened in antagonist mode. A number of stress response pathway assays, including ATAD2-bla[^33], a hereditary polycystic kidney disease-associated response element (ARE-bla)[^34] and heat-shock factor response element (HSE-bla) assays, were screened in agonist mode. Detailed assay protocols can be found in PubChem (http://www.ncbi.nlm.nih.gov/pcassay?term=tox21).

In parallel screening, compounds were tested as three independent runs, with each of the three instances of a compound sample residing in a different location on a different compound plate across replicates. Each replicate set of plates was tested on a different day using a different batch of cells. Analysis of compound concentration–response data was performed as previously described[^3]. Briefly, raw plate reads for each titration point were first normalized relative to the positive control compound (agonist mode: 100%; antagonist mode: 0%) and dimethylsulfoxide (DMSO)–only wells (agonist mode: 0%; antagonist mode: -100%) as follows: % Activity = (V_compound − V_DMSO)/(V_pos − V_DMSO) × 100, where V_compound denotes the compound well values, V_pos denotes the median values of the positive control wells and V_DMSO denotes the median values of the DMSO–only wells, and then corrected by applying an in-house pattern correction algorithm using compound-free control plates (that is, DMSO–only plates) at the beginning and end of the compound plate stack. Concentration–response titration points for each compound were fitted to a four-parameter Hill equation yielding concentrations of half-maximal activity (AC50) and maximal response (efficacy) values. Compounds were designated as CA if concentration–response curve observed[^35]. Curve classes are heuristic measures of data confidence, classifying concentration–responses on the basis of efficacy, the number of data points observed above background activity, and the quality of fit. Each curve class was then converted to a curve rank as previously described[^36,37] such that more specific and efficacious compounds with higher quality curves were assigned a higher rank. Curve ranks should be viewed as qualitative descriptors of the concentration response profile of the compound. Compound reproducibility was assessed by calculating the reproducibility of the curve ranks of each compound generated from the triplicate runs[^3]. A reproducibility score was calculated for each assay using the formula: score = 2 × N active match + N inactive match × 2 × mismatch[^38,39].

### Data Sources

All Tox21 phase II qHTS data are available in PubChem (http://www.ncbi.nlm.nih.gov/pcassay?term=tox21; see Accession Codes section for assay IDs). In vivo toxicity data were retrieved from the Registry of Toxic Effects of Chemical Substances database compiled by Leadscope (Leadscope, Inc.). This compilation contains 129 different toxicity end points including acute toxicity, hepatotoxicity, reproductive toxicity, carcinogenicity and skin and eye irritation from various species such as human, rodents, primates and birds on >10,000 molecules, 6,447 of which overlap with compounds in the Tox21 10 K library. Most of these compounds do not have data available for every toxicity end point; the highest data points for each unique assay/compound/tissue pair represent 50 active/non-toxic calls were kept for further analysis. A total of 68 of the 129 end points met this data availability requirement. In addition, we created three composite end points by aggregating the acute toxicity, reproductive toxicity and the tumorigenic end points, respectively, for a total of 72 end points. For compounds with LD₅₀ data available, an LD₅₀ of <300 mg kg⁻¹ was considered toxic[^35]. For other end points, compounds with toxicity measures falling into the top 35 percentile were considered toxic. For composite end points, compounds that are toxic in more than half of the component end points were considered toxic for the composite call. The 72 selected end points and the number of toxic/non-toxic end points that fall into the same cluster. More significant P-values (larger –log P-values) indicate a larger probability of toxicity. If a cluster was deficient of toxic compounds, that is, the fraction of toxic compounds in the cluster was smaller than the fraction of toxic compounds in the whole library, the log P-value was used instead. Here we denote the toxicity scores obtained from the activity SOM as p-activity, those from the structure SOM as p-structure, and those using both the activity and structure SOM as p-both. To test model performance, the corresponding SOM cluster or consensus cluster was located for each test set point and p-activity, p-structure or p-both obtained from the training set was retrieved and compared with the true toxicity outcome of the test compound to determine whether the test compound should be counted as a true positive (TP: toxic and score > cutoff), false positive (FP: non-toxic and score > cutoff), true negative (TN: non-toxic and score ≤ cutoff) or false negative (FN: toxic and score ≤ cutoff). Model performance was assessed by calculating the AUC-ROC, which is the area under the receiver operating characteristic (ROC) curve (ranging to 1). A perfect model would have an AUC-ROC of 1 and an AUC-ROC of 0.5 indicates a random classifier. The random data split and model training and testing were repeated 100 times, and the average AUC-ROC values were calculated for each model.

### References

1. Collins, F. S., Gray, G. M. & Bucher, J. R. Toxicology. Transforming environmental health protection. Science 319, 906–907 (2008).
2. Kavlock, R. J., Austin, C. P. & Rice, T. R. Toxicity testing in the 21st century: implications for human health risk assessment. Risk Anal. 29, 485–487 (2009).
3. Tice, R. R., Austin, C. P., Kavlock, R. J. & Bucher, J. R. Improving the human hazard characterization of chemicals: A Tox21 update. Environ. Health Perspect. 121, 756–765 (2013).
4. NRC Toxicity Testing in the 21st Century: A Vision and a Strategy (The National Academies Press, 2007).
5. Huang, R. et al. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ. Health Perspect. 119, 11–18 (2011).
6. Shukla, S. J., Huang, R., Austin, C. P. & Xia, M. The future of toxicity testing: a focus on in vitro methods using a quantitative high throughput screening platform. Drug Discov. Today 15, 997–1007 (2010).
7. Attene-Ramos, M. S. et al. The Tox21 robotic platform for the assessment of environmental chemicals - from vision to reality. Drug Discov. Today 18, 717–723 (2013).
8. Hsu, C. W. et al. Quantitative high-throughput profiling of environmental chemicals and drugs that modulate farnesoid X receptor. Sci. Rep. 4, 6437 (2014).
9. Huang, R. et al. Profiling of the Tox21 10 K compound library for agonists and antagonists of the estrogen receptor alpha signaling pathway. Sci. Rep. 4, 5664 (2014).
10. Attene-Ramos, M. S. et al. Profiling of the Tox21 chemical collection for mitochondrial function to identify compounds that acutely decrease mitochondrial membrane potential. Environ. Health Perspect. 123, 49–56 (2015).
11. Zhang, J. H., Chung, T. D. & Oldenburg, K. R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 4, 67–73 (1999).
12. Babula, P., Masarik, M., Adam, V., Provanilk, L. & Kizek, R. From Na+/K+/ATPase and cardiac glycosides to cytotoxicity and cancer treatment. Anticancer Agents Med. Chem. 13, 1069–1087 (2013).
13. Abd, T. T. & Jacobson, T. A. Statin-induced myopathy: a review and update. J. Biomol. Screen. 18, 1069–1087 (2013).
14. Babula, P. et al. The alkylation carcinogen N-methyl-N-nitro-N-nitrosoguanidine activates the phosphoinositide activator inhibitor 1 gene through sequential phosphorylation of p53 by ATM and ATR kinases. Thromb. Haemost. 93, 584–591 (2005).
15. Rogers, J. A., Metz, L. & Yong, V. W. Review: endocrine disrupting chemicals and immune responses: a focus on bisphenol-A and its potential mechanisms. Mol. Immunol. 53, 421–431 (2012).
16. Medjakovic, S. et al. Effect of nonpersistent pesticides on estrogen receptor, androgen receptor, and aryl hydrocarbon receptor. Toxicol. Sci. 29, 1201–1216 (2002).
17. Kirpichnikov, D., McFarlane, S. I. & Sowers, J. R. Metformin: an update. Ann. Intern. Med. 137, 25–33 (2002).
18. Carty, T. J. et al. Ampiroxicam, an anti-inflammatory agent which is a prodrug of piroxicam. Agents Actions 39, 157–165 (1993).
19. Judson, R. et al. Perspectives on validation of high-throughput assays supporting 21st century toxicity testing. ALTEX 30, 51–56 (2013).
20. Huang, R. et al. Characterization of diversity in toxicity mechanism using in vitro cytotoxicity assays in quantitative high throughputscreening. Chem. Res. Toxicol. 21, 659–667 (2008).
21. FDA. Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products. http://www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/ucm077262.htm (2004).
22. Martic-Kehl, M. I., Schibli, R. & Schubiger, P. A. Can animal data predict human outcome? Problems and pitfalls of translational animal research. Eur. J. Nucl. Med. Mol. Imaging 39, 1492–1496 (2012).
23. Walsh, E., Nilsson, M., Cledenson, C. & Ekwall, B. The MEIC program and its implications for the prediction of acute human systemic toxicity. Alternative Methods Toxicol. Life Sci. 11, 275–282 (1995).
24. Goldberg, A. M. & Frazier, J. M. Alternatives to animals in toxicity testing.
25. Low, Y. S., Sedykh, A., Rusyn, I. & Tropsha, A. Integrative approaches for predicting in vivo effects of chemicals from their structural descriptors and the results of short-term biological assays. Curr. Top. Med. Chem. 14, 1356–1364 (2014).
26. Abdo, N. et al. Population-based hazard and concentration-response assessment of chemicals: The 1000 Genomes High-Throughput Screening Study. Environ. Health Perspect. 123, 458–466 (2015).
27. Eduati, F. et al. Prediction of human population responses to toxic compounds by a collaborative competition. Nat. Biotechnol. 33, 933–940 (2015).
28. Huang, R. et al. The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics. Sci. Transl. Med. 3, 80ps16 (2011).
29. Wong, C. & Chen, S. The development, application and limitations of breast cancer cell lines to study tamoxifen and aromatase inhibitor resistance. J. Steroid Biochem. Mol. Biol. 131, 83–92 (2012).
30. Chen, S. et al. Cell-based high-throughput screening for aromatase inhibitors in the Tox21 10 K library. Toxicol. Sci. 147, 446–457 (2015).
31. Sakamura, S. et al. Application of a homogenous membrane potential assay to assess mitochondrial function. Physiol. Genomics 44, 495–503 (2012).
32. Yamamoto, K. N. et al. Characterization of environmental chemicals with potential for DNA damage using isogenic DNA repair-deficient chicken DT40 cell lines. Environ. Mol. Mutagen 52, 547–561 (2011).
33. Fox, J. T. et al. High-throughput genotoxicity assay identifies antioxidants as inducers of DNA damage response and cell death. Proc. Natl. Acad. Sci. USA 109, 5423–5428 (2012).
34. Shukla, S. J. et al. Profiling environmental chemicals for activity in the antioxidant response element signaling pathway using a high throughput screening approach. Environ. Health Perspect. 120, 1150–1156 (2012).
35. Inglese, J. et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc. Natl. Acad. Sci. USA 103, 11473–11478 (2006).
36. GHS United Nations, Globally Harmonized System of Classification and Labelling of Chemicals (GHS) http://www.unece.org/fileadmin/DAM/trans/danger/publi/ghs/ghs_rev02/English/03e_part3.pdf (2007).
37. Kohonen, T. Self-organizing neural projections. Neural Netw. 19, 723–733 (2006).
38. Zweig, M. H. & Campbell, G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin. Chem. 39, 561–577 (1993).

Acknowledgements
This work was supported by the Intramural Research Programs of the National Toxicology Program (Interagency agreement #Y2-ES-7029-01), National Institute of Environmental Health Sciences, the US Environmental Protection Agency (Interagency Agreement #Y3-HG-7026-03) and the National Center for Advancing Translational Sciences, National Institutes of Health. We also thank Nicole Miller, Samuel Michael and Carleen Klumpp-Thomas for assisting with the screens, Paul Shinn, Misha Ikin and Danielle VanLeer for compound management and William Leister for the Tox21 10 K library quality control.

Author contributions
R.H., M.X., C.P.A and A.S designed the study. S.S., I.Z., S.A.S and M.A.R performed the experiments and collected data. R.H. performed statistical analysis of all data. T.Z. aided data analysis and visualization. R.H. and M.X. wrote the manuscript. All authors reviewed the manuscript. The views expressed in this article are those of the authors and do not necessarily reflect the statements, opinions, views, conclusions or policies of the National Center for Advancing Translational Sciences, National Institutes of Health, or the United States government. Mention of trade names or commercial products does not constitute endorsement or recommendation for use.

Additional information
Accession codes: All Tox21 phase II qHTS data have been deposited in PubChem under the following assay IDs: ATAD5: 651632, 720516, 651634; DT40 Rad54l: 70743015; DT40 Rev3: 743014; DT40 WT: 743015; P53-bla: 651631, 720552, 651633; ARE-bla: 743202, 743219, 743203; HSE-bla: 743210, 743228, 743209; aromatase: 743083, 743139, 743084; mitochondria toxicity: 720635, 720637, 720634; AhR-luc: 743085, 743122, 743086; AR-bla agonist: 743036, 743053; AR-bla antagonist: 743035, 743063, 743033; AR-MDA-luc agonist: 743040; AR-MDA-luc antagonist: 743042, 743054, 743041; ER-BG1-luc agonist: 743079; ER-BG1-luc antagonist: 743080, 743091, 743081; ER-bla agonist: 743075, 743077; ER-bla antagonist: 743069, 743078, 743074; FXR-bla agonist: 743220, 743239, 743218; FXR-bla antagonist: 743217, 743240, 743221; GR-bla agonist: 720691, 720719; GR-bla antagonist: 720692, 720725, 720693; PPAR-delta-bla agonist: 743212, 743227, 743211; PPAR-delta-bla antagonist: 743215, 743226, 743213; PPAR-gamma-bla agonist: 743094, 743140; PPAR-gamma-bla antagonist: 743191, 743199, 743194; TR-beta-luc agonist: 743066; TR-beta-luc antagonist: 743065, 743067, 743064; VDR-bla agonist: 743222, 743241, 743224; VDR-bla antagonist: 743223, 743242, 743225.

Supplementary Information
accompanied this paper at http://www.nature.com/naturecommunications

Competing financial interests: The authors declare no competing financial interests.

Reprints and permission information is available online at http://npg.nature.com/reprintsandpermissions/

How to cite this article: Huang, R. et al. Modelling the Tox21 10 K chemical profiles for in vivo toxicity prediction and mechanism characterization. Nat. Commun. 7:10425 doi: 10.1038/ncomms10425 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.